ReviewMicroorganisms2025
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Genetic profiling of biofilm-associated genes (bap, ompA, csuE, and blaPER-1) in Acinetobacter baumannii clinical isolates.Archives of microbiology · 2026Article
- Site-specific and time-varying Acinetobacter colonization and risk of invasive infection in critically ill patients.Infection · 2026Article
- Beyond Colonization: Dynamic Risk Stratification and Clinical Decision-Making for MDR Gram-Negative Infections in Critically Ill Patients.Biomedicines · 2026Review
- An Integrated Computational and Biophysical Approach for Investigating the Structure-Function Impact of blaOXA-58 Mutations in Acinetobacter baumannii.Molecular biotechnology · 2026Article
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Mechanistic and clinical insights into a PmrB mutation driving colistin resistance and virulence in Acinetobacter baumannii.Scientific reports · 2026Article
- Development and validation of an interpretable machine learning-based model for predicting carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- Prioritization of antimicrobial resistance surveillance of gram-negative pathogens - a stacked modelling approach.Wellcome open research · 2026Article
- YtnP lactonase fromFrontiers in microbiology · 2026Article
- Comprehensive in silico analysis of Acinetobacter isolates from South Korea reveals genomic diversity, antimicrobial resistance, virulence factors, and evolutionary dynamics.Genes & genomics · 2026Article
- Evaluation of Wound Infections after the 2023 Kahramanmaraş Earthquakes.Infectious diseases & clinical microbiology · 2026Article
- Patients and Surfaces: Integrated Clinical-Environmental Surveillance of MDR Gram-Negative Bacteria in Critical-Care Units (Karachi, 2024-2025).Microorganisms · 2025Article
- Antimicrobial Resistance of Non-Fermenting Gram-Negative Bacilli in a Multidisciplinary Hospital in Romania.Biomedicines · 2025Article
- Evaluation of Infections Caused by Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.